548 Effects of a natural immune modulator on plaque psoriasis N Korman, E Baron, K Gordon, S Glazer, S Phillips and JE Bernstein 1 University Hospitals, Cleveland, OH, 2 Northwestern University, Chicago, IL, 3 Northshore University Health System, Evanston, IL and 4 Elorac, Inc., Vernon Hills, IL Background: Recognition that psoriasis (PS) is a chronic inflammatory disorder, rather than a local hyperproliferative disorder, has led to the understanding that proinflammatory cytokines contribute to the initiation and/or persistence of inflammation in PS. These cytokines and their transduction pathways, include tumor necrosis factor alpha (TNF-a), various interleukins (IL), the Janus kinases and phosphodiesterase 4. Objective: To evaluate oral administration of a natural immune modulator(NIM) to patients with plaque PS receiving concomitant treatment with biological drugs, and effects of NIM on inflammatory biomarkers in treatment-naive PS patients. Methods: Nineteen (19) adult PS patients receiving a biologic (ustekinumab (9), adalimumab (7), etanercept (3)) for at least 3mo received NIM capsules qd for 8wks. Clinical benefits were assessed by a Self-Administered Psoriasis Area Severity Index (SAPASI), a patient global, and an evaluation of body surface area (BSA). Nineteen (19) PS patients without therapy for 90 days, or biological for 1yr, received NIM for 28 days. Serum TNF-a, IL-6 and IL-12 biomarkers were measured at baseline and at 28 days. Adverse effects (AE) were solicited. Results: Baseline SAPASI scores ranged from 4-60 (mean of 16.5). These scores were reduced to a mean SAPASI of 6.7 at 8wk. Of 11 patients with a baseline SAPASI>10, 91% had an 8wk PASI 50 and 55% had an 8wk PASI 75. Patient globals demonstrated that 63% of patients were Much Better or Better. Ten (10) patients (53%) had a substantial BSA decrease in. Eleven (11) of 19 patients had a decrease in serum TNF-a levels with a mean decrease of 18.6% and 10 of the 19 patients (53%) had a 47.3% mean reduction in IL-6/IL-12 serum levels. No NIM related AE were reported. Conclusions: Addition of NIM to PS patients on biologicals can provide additional clinical benefit, and the actions of the NIM may be related to its ability to inhibit a variety of inflammatory pathways critical to PS. 549 Antioxidative Activity of CSL Extracts on normal human epidermis J Shim Department of Oriental Cosmetic Science, Semyung Univ, Jecheon, Korea (the Republic of) In this study, the antioxidative effects of CSL extracts were investigated. CSL extract has the similar antioxidant activity compared to ascorbic acid by DPPH assay. To confirm the antioxidnat effect on human epiermal keratinocyte, we treated CSL extract on UVA (5 J/cm2) treated human epidermal keratinocyte. CSL extract can enhance the expression of AQP3 and HAS2 genes. And CSL extract reduced the H2O2 production by UVA treatment. To determine the cause of antioxidnat activity on human epidermal keratinocyte, we performed realtime PCR related on antioxidnat enzymes such as SODs, catalase, and GPXs. Only GPX7 mRNA expression was enhanced by CSL extract treatment. These results mean that CSL extract have radical scaveging and inducing the expression of antioxidant enzyme especially GPX7. And component analysis of CSL extract and antioxidant activity could be applicable to new functional cosmetics.
Read full abstract